95% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Naveen Kumar Velayutham1
Tamilanban Thamaraikani1*
Shadma Wahab2Mohammad Khalid3
Gobinath Ramachawolran4*Shahabe Saquib Abullais5
Ling Shing Wong6*
Mahendran Sekar7,8*
Siew Hua Gan7
Angel Jemima Ebenezer9
Mrinalini Ravikumar1
Vetriselvan Subramaniyan10
Nur Najihah Izzati Mat Rani11
Yuan Seng Wu12
Srikanth Jeyabalan13- 1Department of Pharmacology, SRM College of Pharmacy, SRM Institute of Science and Technology, Chennai, Tamil Nadu, India
- 2Department of Pharmacognosy, College of Pharmacy, King Khalid University, Abha, Saudi Arabia
- 3Department of Pharmacognosy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia
- 4Department of Foundation, RCSI and UCD Malaysia Campus, George Town, Malaysia
- 5Department of Periodontics and Community Dental Sciences, College of Dentistry, King Khalid University, Abha, Saudi Arabia
- 6Faculty of Health and Life Sciences, INTI International University, Nilai, Malaysia
- 7School of Pharmacy, Monash University Malaysia, Subang Jaya, Selangor, Malaysia
- 8Center for Transdisciplinary Research, Department of Pharmacology, Saveetha Dental College, Saveetha Institute of Medical and Technical Science, Chennai, India
- 9Trichy Research Institute of Biotechnology Pvt Ltd., Trichy, Tamil Nadu, India
- 10Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Subang Jaya, Selangor, Malaysia
- 11Faculty of Pharmacy and Health Sciences, Royal College of Medicine Perak, Universiti Kuala Lumpur, Ipoh, Perak, Malaysia
- 12Department of Biological Sciences and Centre for Virus and Vaccine Research, School of Medical and Life Sciences, Sunway University, Subang Jaya, Selangor, Malaysia
- 13Department of Pharmacology, Sri Ramachandra Faculty of Pharmacy, Sri Ramachandra Institute of Higher Education and Research (DU), Chennai, Tamil Nadu, India
A Corrigendum on
Stylopine: a potential natural metabolite to block vascular endothelial growth factor receptor 2 (VEGFR2) in osteosarcoma therapy
by Velayutham NK, Thamaraikani T, Wahab S, Khalid M, Ramachawolran G, Abullais SS, Wong LS, Sekar M, Gan SH, Ebenezer AJ, Ravikumar M, Subramaniyan V, Mat Rani NNI, Wu YS and Jeyabalan S (2023). Front. Pharmacol. 14:1150270. doi: 10.3389/fphar.2023.1150270
In the published article, there was an error in the Article Title. Instead of “Stylopine: A potential natural metabolite to activate vascular endothelial growth factor receptor 2 (VEGFR2) in osteosarcoma therapy,” it should be “Stylopine: A potential natural metabolite to block vascular endothelial growth factor receptor 2 (VEGFR2) in osteosarcoma therapy.”
Additionally, there was an error in the Conflict of Interest statement. The original statement omitted the declaration for commercial affiliations. The correct Conflict of Interest statement appears below.
Conflict of interest
Author AE was employed by Trichy Research Institute of Biotechnology Pvt Ltd.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: benzylisoquinoline alkaloids, stylopine, MG-63, osteosarcoma, VEGFR2
Citation: Velayutham NK, Thamaraikani T, Wahab S, Khalid M, Ramachawolran G, Abullais SS, Wong LS, Sekar M, Gan SH, Ebenezer AJ, Ravikumar M, Subramaniyan V, Izzati Mat Rani NN, Wu YS and Jeyabalan S (2024) Corrigendum: Stylopine: a potential natural metabolite to block vascular endothelial growth factor receptor 2 (VEGFR2) in osteosarcoma therapy. Front. Pharmacol. 15:1343756. doi: 10.3389/fphar.2024.1343756
Received: 24 November 2023; Accepted: 08 January 2024;
Published: 17 January 2024.
Edited and reviewed by:
Shoib Sarwar Siddiqui, University of Hertfordshire, United KingdomCopyright © 2024 Velayutham, Thamaraikani, Wahab, Khalid, Ramachawolran, Abullais, Wong, Sekar, Gan, Ebenezer, Ravikumar, Subramaniyan, Izzati Mat Rani, Wu and Jeyabalan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Tamilanban Thamaraikani, dGFtaWxhbnRAc3JtaXN0LmVkdS5pbg==; Gobinath Ramachawolran, ci5nb2JpbmF0aEByY3NpdWNkLmVkdS5teQ==; Mahendran Sekar, bWFoZW5kcmFuLnNla2FyQG1vbmFzaC5lZHU=; Ling Shing Wong, bGluZ3NoaW5nLndvbmdAbmV3aW50aS5lZHUubXk=